Figure 1

Effects of ipragliflozin on blood glucose levels, body weights, BP, and urine volumes in db/db mice. (a) High-dose ipragliflozin significantly inhibited further increases in blood glucose levels in db/db mice. (b) The ipragliflozin treatment did not affect systolic BP. (c) High-dose ipragliflozin inhibited body weight gain in db/db mice. (d) Urine volume was significantly lower in ipragliflozin-treated db/db mice. (e) Pictures of M-mode echocardiography. (f) The ipragliflozin treatment reduced the left ventricular chamber size of db/db mice. Data show the means ± SD, *p < 0.05 vs db/db (−), ^#p < 0.05 vs db/db-LD, ^†p < 0.05 vs db/db-HD, Bar = 1 mm in (e), n = 4–5 mice in each group, one-way ANOVA, Tukey’s multiple comparison.